Dual ALDOA–PGK1 inhibition shows antitumor synergy in preclinical oral squamous cell carcinoma models
Background
A preclinical study found antitumor activity from jointly inhibiting the glycolytic enzymes ALDOA and PGK1 in oral squamous cell carcinoma (OSCC). The inhibitor combination showed synergy in a Bliss independence analysis and suppressed tumors more than either drug alone in a xenograft tumor model.
OSCC remains challenging because of its high mortality and the lack of effective targeted therapies. Metabolic reprogramming in cancer cells is closely linked to malignant traits, but key metabolic regulators that functionally contribute to OSCC progression and could serve as therapeutic targets have not been sufficiently identified. The researchers combined patient transcriptome data with gene-function analyses to narrow down prognosis-associated genes on which cancer cells depend for survival, then examined whether inhibiting them reduced tumor growth.
Key findings
The researchers first applied LASSO regression to transcriptome data from the OSCC cohort of The Cancer Genome Atlas (TCGA) to construct a set of prognosis-associated genes. They then assessed gene essentiality and tumor selectivity using large-scale CRISPR-Cas9 gene-dependency data from the Cancer Dependency Map (DepMap).
This process identified the glycolytic enzymes aldolase A (ALDOA) and phosphoglycerate kinase 1 (PGK1) as candidate targets that were both associated with prognosis and highly depended upon by OSCC cell lines. In patient data, high ALDOA and PGK1 expression was significantly associated with poorer survival. This association alone, however, does not establish that the two enzymes directly cause a worse prognosis in patients.
Silencing the expression of either ALDOA or PGK1 reduced glycolytic activity in cancer cells. A decrease in the extracellular acidification rate (ECAR) supported this finding. ECAR measures the rate at which the extracellular environment becomes acidic and was used here as an indicator of changes in glycolytic activity. The abstract did not present this as a direct measurement of lactate secretion. The researchers also reported inhibition of tumor-cell proliferation in vitro and in vivo.
A drug combination inhibiting both enzymes also showed antitumor activity. Combining the ALDOA inhibitor aldometanib (Aldometanib) with the PGK1 inhibitor CBR-470-1 showed synergy in a Bliss independence analysis. In a xenograft tumor model, the combination group also showed greater tumor suppression than either single-drug group. However, the provided abstract did not specify the magnitude of the combination effect, drug doses, or dosing schedule.
Implications and outlook
By adding gene-function and drug-combination experiments to analyses of prognostic associations in patient data, this study provides a basis for further evaluation of dual ALDOA–PGK1 inhibition. It brings together analyses identifying targets associated with patient survival and experiments testing the effects of target inhibition in preclinical models.
However, the combination's synergy and tumor suppression do not demonstrate that it blocks metabolic bypass pathways or overcomes drug resistance. Whether ALDOA and PGK1 expression levels can predict treatment response or guide patient selection also remains unconfirmed. Further evaluation of the combination's reproducibility and safety is needed to assess its potential for clinical application.
The available materials consist of the abstract and bibliographic record; the patient count, cell lines used, animal count, quantitative effect sizes, and toxicity findings could not be verified. These findings should also be distinguished from clinical-trial results demonstrating treatment effects in patients. The study was published in Discover Oncology, and its main findings are available in the paper abstract.
BACKGROUND: Oral squamous cell carcinoma (OSCC) is associated with high mortality and limited effective targeted therapies. Although metabolic reprogramming is closely linked to malignancy, the key metabolic regulators that functionally drive OSCC progression and may serve as therapeutic targets remain incompletely defined. METHODS: We combined clinical transcriptomic analysis with functional genomic screening to identify metabolic vulnerabilities in OSCC. A Least Absolute Shrinkage and Selection Operator (LASSO)-derived prognostic gene signature was constructed using transcriptomic data from The Cancer Genome Atlas (TCGA)-OSCC cohort. To prioritize functionally critical targets, gene essentiality and tumor selectivity were evaluated using large-scale CRISPR-Cas9 dependency data from the Cancer Dependency Map (DepMap) project. RESULTS: This analysis identified Aldolase A (ALDOA) and Phosphoglycerate Kinase 1 (PGK1) as candidate targets with prognostic relevance and strong dependency across OSCC cell lines. Elevated expression of ALDOA and PGK1 was significantly associated with poor patient survival. Mechanistically, genetic silencing of ALDOA or PGK1 impaired glycolytic activity, as evidenced by reduced extracellular acidification rates (ECAR), and suppressed tumor cell proliferation in vitro and in vivo. Furthermore, combined targeting of these two glycolytic enzymes produced synergistic anti-tumor effects. Bliss independence analysis showed synergy between the ALDOA inhibitor Aldometanib and the PGK1 inhibitor CBR-470-1, and the combination produced greater tumor suppression than either monotherapy in xenograft models. CONCLUSION: Our findings indicate that ALDOA and PGK1 contribute to metabolic reprogramming and poor prognosis in OSCC. These findings support further evaluation of dual ALDOA and PGK1 inhibition as a potential therapeutic strategy for OSCC.
The practical significance of this study is that it proposes a combination of metabolic targets for evaluation in follow-up preclinical research. For example, researchers could design studies comparing whether dual ALDOA–PGK1 inhibition produces greater effects than single-target inhibition in other experimental OSCC models and assessing safety under the conditions in which an effect is observed. The association between high expression and poor survival in patient data leaves a separate question for validation. Until expression levels are shown to predict actual response to the combination treatment, these findings cannot support a companion diagnostic or prioritizing patients with high expression for treatment. The current results provide a starting point for deciding whether to pursue further development of this target combination.